Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.62 |
| ▸ | CPT2 | P23786 | 1/20 | 0.62 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1831810 | 1.00 | TDP1 (0.62) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL4184422 | 1.00 | TDP1 (0.62) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL14360000 | 0.95 | TDP1 (0.58) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL27628078 | 0.95 | TDP1 (0.58) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL14359845 | 0.93 | TDP1 (0.54) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL7864001 | 0.91 | GPR84 (0.58) | TDP1FFAR1CPT2TSHRGPR84 | |
| SCHEMBL1116137 | 0.91 | GPR84 (0.58) | TDP1FFAR1CPT2TSHRGPR84 | |
| SCHEMBL3280282 | 0.91 | TDP1 (0.54) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL6696708 | 0.91 | GPR84 (0.54) | TDP1FFAR1CPT2TBXAS1TSHR | |
| SCHEMBL1116131 | 0.91 | GPR84 (0.58) | TDP1FFAR1CPT2TSHRGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001755-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROME X LTD (IL) | 2011-05-11 | — | — | EP | claimed |
| US-20100240683-A1 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | SYNDROMEX LTD. (IL) | 2010-09-23 | — | — | US | claimed |
| US-20100113599-A1 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | SYNDROMEX LTD. C/O YISSUM RESEARCH DEVELOPMENT COMPANY, OF (IL) | 2010-05-06 | — | — | US | claimed |
| EP-2131832-A2 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | Syndromex Ltd. (IL) | 2009-12-16 | — | — | EP | claimed |
| EP-0988274-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROMEX LTD (IL) | 2009-05-20 | — | — | EP | claimed |
| WO-2008104976-A1 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | SYNDROMEX LTD. (IL) | 2008-09-04 | — | — | WO | claimed |
| WO-2008104975-A2 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | SYNDROMEX LTD. (IL) | 2008-09-04 | — | — | WO | claimed |
| US-20040171585-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | BAR-TANA JACOB (IL) | 2004-09-02 | — | — | US | claimed |
| US-20040171688-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | BAR-TANA JACOB (IL) | 2004-09-02 | — | — | US | claimed |
| US-20020037876-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM | 2002-03-28 | — | — | US | claimed |
| US-6284903-B1 | TREATING HYPERLIPIDEMIA, OBESITY AND IMPAIRED GLUCOSE TOLERANCE/NONINSULIN DEPENDENT DIABETES MELLITUS WITHOUT ADVERSELY AFFECTING ENERGY METABOLISM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-09-04 | — | — | US | claimed |
| EP-0988274-A4 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2000-10-18 | — | — | EP | claimed |
| EP-0988274-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-03-29 | — | — | EP | claimed |
| WO-1998030530-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | claimed |
| EP-2112134-B1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | SYNDROMEX LTD (IL) | 2013-10-30 | — | — | EP | disclosed |
| EP-1001755-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROME X LTD (IL) | 2011-05-11 | — | — | EP | disclosed |
| US-20100240683-A1 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | SYNDROMEX LTD. (IL) | 2010-09-23 | — | — | US | disclosed |
| EP-0988274-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-03-29 | — | — | EP | disclosed |
| WO-1999000116-A2 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998030530-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240683-A1 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | HMGCR, APOB, CETP | TDP1 2506/4885FFAR1 71/4885CPT2 45/4885 |
| US-20100113599-A1 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | MALT1, TLR9, TLR6 | TDP1 1097/4885FFAR1 157/4885CPT2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.